Bank of Montreal Can Purchases 1,169,044 Shares of Catalent, Inc. (NYSE:CTLT)

Bank of Montreal Can raised its position in shares of Catalent, Inc. (NYSE:CTLT) by 181.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,813,167 shares of the company’s stock after buying an additional 1,169,044 shares during the quarter. Bank of Montreal Can owned about 1.00% of Catalent worth $109,388,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CTLT. Millennium Management LLC lifted its position in Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after acquiring an additional 2,299,784 shares during the last quarter. Alpine Associates Management Inc. raised its position in shares of Catalent by 3.4% in the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock valued at $129,082,000 after purchasing an additional 69,875 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Catalent by 14.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock worth $108,559,000 after purchasing an additional 250,999 shares in the last quarter. Marshall Wace LLP grew its position in Catalent by 5.1% during the 2nd quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock worth $100,818,000 after purchasing an additional 86,533 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Catalent by 1.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,656,506 shares of the company’s stock valued at $100,335,000 after purchasing an additional 17,681 shares in the last quarter.

Insider Activity

In related news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on CTLT. StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. Robert W. Baird reiterated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat.com, Catalent has a consensus rating of “Hold” and an average target price of $63.40.

Catalent Trading Down 0.9 %

Shares of Catalent stock opened at $60.76 on Wednesday. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a market capitalization of $11.03 billion, a price-to-earnings ratio of -26.88, a PEG ratio of 2.42 and a beta of 1.16. The stock has a 50 day moving average of $59.83 and a 200 day moving average of $58.36.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the business posted ($0.10) earnings per share. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.